| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Anika Therapeutics, Inc. (ANIK) has 5 insiders with recent SEC Form 4 filings, including 0 buys and 16 sells. ANIK is classified in the Pharmaceuticals industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 211.4K | $3.00M | - | |
| Dir | 54.9K | $779.2K | - | |
| CEO | 36.2K | $513.5K | - | |
| VP | 13.1K | $186.0K | - | |
| VP | 0 | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2017 | Hague Richard | Chief Commercial Officer | Sell | 5,250 | $54.48 | $286,020.00 | -18.2% | |
| Oct 24, 2017 | Sherwood Charles H | CEO And Director | Sell | 3,278 | $60.04 | $196,811.12 | -2.4% | |
| Oct 23, 2017 | Sherwood Charles H | CEO And Director | Sell | 28,219 | $60.06 | $1,694,713.32 | -8.7% | |
| Oct 16, 2017 | Sherwood Charles H | CEO And Director | Sell | 3,293 | $60.04 | $197,711.72 | -100% | |
| Oct 13, 2017 | Sherwood Charles H | CEO And Director | Sell | 7,124 | $60.08 | $428,013.76 | -2.1% | |
| Jul 27, 2017 | Sherwood Charles H | CEO And Director | Sell | 63,799 | $50.79 | $3,240,351.21 | -26.7% | |
| Jul 5, 2017 | Sherwood Charles H | President, CEO, Director | Sell | 14,201 | $50.03 | $710,544.16 | -2.8% | |
| May 22, 2017 | Thompson Jeffery S | Director | Sell | 10,725 | $47.39 | $508,273.62 | -32.7% | |
| Feb 24, 2017 | Ahn Edward S. | Chief Tech &Strategy Officer | Sell | 640 | $49.47 | $31,660.80 | -8.1% | |
| Feb 22, 2017 | Cheung Sylvia | Chief Financial Officer | Sale+OE | 4,000 | $49.02 | $196,095.79 | -3.5% |